

1

2

3

4

5 **A mixed cross-sectional and case-control study approach to**
6 **investigate the risk-factors of Noma/Cancrum oris in**
7 **Ethiopia**

8

9

10 Heron Gezahegn Gebretsadik^{1*}, Laurent Cleenewerck de Kiev²

11 ¹ School of Global Health & Bioethics, Euclid University, Banjul, Gambia

12 ² EUCLID (Euclid University), Bangui, Central African Republic

13

14 * Corresponding author

15 gezahegn.heron@gmail.com

16

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 **Abstract**

18 **Introduction**

19 Noma is a polymicrobial gangrenous facial disease affecting people living in the most
20 impoverished areas of low- and middle-income countries. If left untreated, the disease is fatal
21 or else severely disfigure people with the condition. The compromised immune system, poor
22 oral hygiene, measles infection, diarrheal disease, inaccessibility to health education and
23 proper medical care, and lack of a balanced diet and good sanitary facilities are found to be
24 some of the predisposing factors for the development and progression of the disease.
25 Furthermore, debilitating diseases like malaria and measles were considered as significant
26 precursors to Noma.

27 **Materials and Method**

28 A mix of cross-sectional and case-control study approaches was conducted to assess the risk
29 factors of Noma in Ethiopia. The raw data of the cases were obtained from Yekatik 12
30 Hospital, Facing Africa, and the Harar project Ethiopia. Three controls were selected per single
31 case. The Odd ratio (ORs) and Chi-square test were calculated to rule out the statistical
32 significance of the association observed between the factors and the disease.

33 **Results**

34 A total of 64 cases were selected for the case-control study. Considering the 1:3 case to
35 control ratio, 192 matching controls were identified. Malaria, helminths, measles, diarrheal
36 diseases, and living with domestic animals were found to be risk factors for Noma with a

37 respective p-value < 0.01. Contrarily, the analysis has identified vaccination ($p < 0.01$) as a
38 protective factor.

39 **Discussion**

40 Noma/face of poverty is mostly preventable by providing proper nutrition, sanitary and water
41 facilities, awareness about the disease, oral health education, and vaccinations. Poverty-
42 related diseases such as malaria, helminths infection, measles, diarrheal diseases, and
43 unfavorable living conditions were identified to be the risk factor for Noma. As such the
44 disease is truly preventable. Prevention of the disease can be achieved through promoting
45 overall awareness of the disease, poverty reduction, improved nutrition, and promotion of
46 exclusive breastfeeding in the first 3-6 months of life. Furthermore, optimum prenatal care,
47 timely immunizations against common childhood diseases, initiating vaccination, and
48 improving the social living conditions are the other preventive mechanisms. Moreover, long-
49 lasting economic development should be considered to effectively and sustainably prevent
50 the disease.

51

52 Introduction

53 Noma is a rapidly progressive, polymicrobial, opportunistic, gangrenous infection of the
54 mouth, most likely caused by certain kinds of Burulibacterial flora that switch to pathogenic
55 when the host is immunocompromised (1). Alternatively known as Stomatitis gangrenosa or
56 Cancrum oris, the etiology of Noma is infectious, yet unclear as regards the exact causative
57 microorganism (2). Due to its primary occurrence in young children living in remote areas of
58 the least developed countries with inadequate health systems and its rapid progression rate
59 and high case fatality, today, Noma is a poorly studied disease, and its cause remains
60 idiopathic (3). Because of the potential involvement of bacteria, the transmissibility of Noma
61 has to be considered, but epidemiological patterns and animal experiments currently do not
62 support this possibility (4).

63 Several potential pathogens were found in abundance in the sites of Noma, which include
64 *Prevotella melaninogenica*, *Corynebacterium pyogenes*, *Fusobacterium nucleatum*,
65 *Bacteroides fragilis*, *Bacillus cereus*, *Prevotella intermedia*, and *Fusobacterium necrophorum*.
66 Microbial analysis in the early 20th century revealed the presence of spirilliform and fusiform
67 microorganisms in biopsy samples taken from the transitional zone between gangrenous and
68 healthy tissues (5). Later studies reported that *Fusobacterium necrophorum*, a predominant
69 animal pathogen is the most common microorganism isolated from the disease sites in
70 Nigerian children. It was suggested that *Fusobacterium necrophorum* could be a trigger
71 organism for noma. This microorganism produces various toxins and has been associated with
72 necrotizing infections in animals, and it may contaminate livestock and potentially infect
73 children (6).

74 On the other hand, a recent study has contradicted the involvement of *Fusobacterium*
75 *necrophorum* as an etiologic agent (7). Known periodontal pathogens like *agggregatibacter*
76 *actinomycetemcomitans*, *capnocytophaga*, *porphyromonia*, and *fusobacteria* were more
77 prevalent in healthy samples compared to those with Noma (8). The study also identified
78 *prevotella intermedia* and *peptostreptococcus* to be more clearly associated with Noma (9).

79 Noma is commonly seen in a population with extreme poverty, severe malnutrition, unsafe
80 drinking water, poor sanitation, poor oral health practices, limited access to high-quality
81 health care, and intrauterine growth retardation (10). Recently, an increased incidence of
82 Noma has been reported in patients with Human Immune deficiency Virus (HIV) infection,
83 cyclic neutropenia, leukemia, Down's syndrome, Burkett's disease, and herpetic stomatitis
84 (11).

85 Malnutrition is considered to be an important risk factor for Noma (12). In Africa, most of the
86 cases were reported during the dry season when food is scarce, and when the incidence of
87 measles is highest. Measles could also be an important risk factor because of its associated
88 immunosuppression (13).

89 A retrospective study revealed severe malnutrition, recent respiratory or diarrhoeal
90 syndrome, the number of previous pregnancies in the mother, an altered oral microbiota, and
91 the absence of chickens at home as predictors of Noma (14). Furthermore, lack of maternal
92 care, measles, and malnutrition were reported as risk factors for developing Noma in Nigeria
93 (15) (14).

94 In general, immunodeficiency disorders, including AIDS, down syndrome, malnutrition,
95 dehydration, poor oral hygiene, recent orofacial and systemic illness, unsafe drinking water,
96 poverty, malignancy, and living near domestic animals are reported to be other predisposing

97 factors (16) (17) (18). The unusual case of Noma in a 32-year-old malnourished HIV-
98 seropositive female, within three days, the initial intraoral necrotizing process spread rapidly
99 and caused full circular thickness perforating destruction of the lower lip has shown
100 immunosuppression associated with a high HIV load as an important risk factor in South Africa
101 (19). On many occasions, recent debilitating conditions like measles (commonly), herpes
102 simplex, varicella, scarlet fever, malaria, gastroenteritis, tuberculosis, and
103 bronchopneumonia appear to set the stage for the development of Noma (1). Also,
104 intrauterine growth retardation, down syndrome, exposure to cytomegalovirus, and
105 premature birth have been considered as predisposing factors for the development of Noma.
106 Cases associated with malignancies (e.g., leukemia) are not rare (18).

107 Mortality used to be a common complication of Noma (20). Only approximately 15% of
108 children survive acute Noma. However, with the use of modern antibiotics and better
109 nutrition, the mortality rate has reduced from 90% to 8-10% (21). Most Noma patients have
110 difficulty in mastication because of the loss of soft and hard tissues. Severe cosmetic
111 disfigurement can also take place from the resulting scarring and loss of tissue (22). At a later
112 age, these contractures often lead to growth disturbances and result in further facial
113 disfigurement and functional impairment. The psychological impact of surviving Noma can be
114 easily understood; patients reported high psychiatric morbidity after Noma (23).

115 Noma is a truly enigmatic disease and very little epidemiological global data are available (24).
116 The risk factors of the disease are not also well-understood (25). This explains the extent to
117 which the disease is neglected (26). Yet, the disease affects poor children among the
118 disadvantaged societies throughout the world including Ethiopia (27). This study was initiated
119 to assess the risk factors of Noma in Ethiopia.

120 **Materials and Methods**

121 **Study design**

122 A mix of cross-sectional and case-control study approaches was used to identify the possible
123 risk/predisposing factors that could potentially be associated with the development of Noma
124 in this study. The study matched three controls for each corresponding case in terms of
125 geographic location, gender, and age.

126 **Study location and population**

127 The cross-sectional and case-control studies were conducted in different parts of the country,
128 including Addis Ababa depending on the findings of the demographic-geographic data
129 obtained from patients' medical records review. All the patients' medical records were
130 obtained from the main offices of the three major Noma treatment centers located in Addis
131 Ababa. Cases were patients diagnosed with Noma and treated in Yekatit 12 Hospital, Facing
132 Africa Ethiopia or Harar Project Ethiopia between March 2004 and December 2020. The cases
133 were identified via the cross-sectional study. Controls were individuals that matched to cases
134 by the village of residence, current age (+/- 2 years), and sex.

135 **Case and control definitions**

136 **Definition of case**

137 In this study, cases are individuals who have been diagnosed with Noma in Ethiopia between
138 January 2004 and February 2020. To be ascertained as a case of Noma, an individual should
139 have facial edema, intraoral necrotizing stomatitis, metallic taste, typical halitosis (often
140 considered as pathognomonic), bluish discoloration of the skin, gangrenous demarcation,

141 tissue necrosis, and sloughing. Moreover, three or more of the following should be
142 considered: a history of malnourishment, a history of poor oral hygiene, a history of poverty,
143 a history of poor sanitation and living close to domestic animals, and a history of debilitating
144 and immunocompromising diseases such as measles, tuberculosis, AIDS, leukemia.

145 **Definition of control**

146 Controls are individuals who were never diagnosed with Noma. Furthermore, the controls
147 need to be matched to cases by the village of residence, current age (+/- 2 years), and sex.

148 **Data collection and analysis**

149 The investigator needed to review the medical registers of Noma cases for the 2004-2020
150 period including patients' photos with relevant clinical and demographic information to
151 answer the research questions. A modified case report form (CRF) consisting of demographic
152 and clinical sections was used to collect the relevant demographic and clinical information,
153 respectively (Appendix S1). The demographic section of the CRFs contains the name, gender,
154 age, physical address (geographic location), telephone address, and year of admission of the
155 patients. On the other hand, the clinical section of the CRFs primarily subdues the localization
156 of Noma-induced anatomical lesions, medical history, dietary information, vaccination
157 details, living stands, and functional impairments data.

158 Similarly, a questionnaire with a set of questions was used to interview the cases (caregivers
159 or guardians) and controls (caregivers or guardians) to complete the case-control study
160 (Appendix S2). Therefore, the information regarding the possible risk factors for Noma was
161 obtained using a structured written questionnaire and reviewing patients' medical charts. The
162 questionnaire also consisted of demographic and clinical (risk factor) data. Both the CRFs and
163 questionnaire were made to be valid. The researcher verified the validity of the CRFs and the

164 questionnaire. Furthermore, pre-tests were conducted to assess the validity and reliability of
165 the data collection instruments that were used in this case-control study.

166 On the other hand, the contact information of the cases, including patient name, telephone
167 number, and home address, were obtained from the CRFs and used to select neighboring
168 controls. The controls were explored for the necessary demographic and clinical information
169 to carry out the case-control study. The data analysis of the case-control study follows the
170 entry of relevant clinical and demographic data of the cases and controls into an excel sheet.
171 Descriptive analysis was used to determine the characteristics of cases and controls. The odds
172 ratio (OR) was calculated to rule out the existing association between the possible
173 risk/predisposing factors and the disease. A Chi-square test was carried out to test the
174 statistical significance of the associations observed between the predisposing factors and the
175 condition.

176 **Ethical consideration**

177 The Addis Ababa Health Bureau has given the necessary in-country ethical clearance. Oral
178 consent was received from all the study participants before starting the interview to complete
179 the questionnaire. The interviewees were fully informed about the study and its purpose,
180 expected risks or benefits from participation, and confidentiality of information. All the
181 information was treated secretly. Moreover, the researcher used patients' initials in the excel
182 sheet.

183 **Results**

184 The case-control study was employed to identify the possible risk factors to develop Noma
185 among the cases. The cases were selected from the medical records obtained from the three

186 Noma treatment centers (Yekatit 12 Hospital, Facing Africa, and Harar Project). Completeness
187 of medical records, availability of pertinent contact information (at least phone number), and
188 age of the patient during admission were the criteria to select the 64 cases.

189 Out of the 163 Noma patients who had sought care in the programs between March 2004
190 and December 2020, 64 were eligible for inclusion in the case-control study. Of these, one
191 could not be located for logistical reasons, and the researcher managed to interview the study
192 participant via phone. Thus, the final analysis included 64 Noma cases and 192 controls. All
193 cases and controls were under 41 years old. The age restriction was considered to avoid recall
194 bias. The assumed potential risk factors were living with domestic animals, having diarrheal
195 disease, having a helminthic infection, exposure to malaria infection, being inflicted with
196 measles infection, and drinking river (Tables 1-6).

197 **Table 1. Domestic animals at home (2 x 2 table)**

	Cases	Controls	Total
Present	35	43	78
Not-present	29	149	178
Total	64	192	256

198

199

200 **Table 2. Diarrheal disease (2 x 2 table)**

	Cases	Controls	Total
Present	35	43	78
Not present	29	149	178
Total	64	192	256

201

202 **Table 3. Helminthic infection (2 x 2 table)**

	Cases	Controls	Total
Present	31	12	43
Not present	33	180	213
Total	64	192	256

203

204 **Table 4. Malaria infection (2 x 2 table)**

	Cases	Controls	Total
Present	21	14	35
Not present	43	178	221
Total	64	192	256

205

206

207 **Table 5. Measle infection (2 x 2 table)**

	Cases	Controls	Total
Present	13	14	27
Not present	51	178	229
Total	64	192	256

208

209 **Table 6. Drinking river water (2 x 2 table)**

	Cases	Controls	Total
Drinks	15	41	56
Not drink	49	151	200
Total	64	192	256

210

211 On the other hand, vaccination was regarded as a potential protective factor based on the
212 literature review (Table 7).

213

214 **Table 7. Vaccination (2 x 2 table)**

	Cases	Controls	Total
Vaccinated	14	104	118
Non-vaccinated	50	88	138
Total	64	192	256

215

216 The clinical information obtained from the patients' medical records were the main guiding
217 principles to consider these as a potential risk and protective factors for Noma. Accordingly,
218 each potential risk factor and the vaccination as protective factors were assessed for having
219 a statistically significant association with the occurrence of Noma.

220 In conclusion, malaria, helminthic and measles infections, living with domestic animals, and
221 diarrheal diseases are identified to be risk/predisposing factors for the development of Noma.
222 On the contrary, drinking river water has shown no significant association with the
223 development of Noma among the cases. On the other hand, vaccination is found to be a
224 protective factor not to develop Noma among the controls.

225

226 **Table 8. Summary of risk and protective factors**

Risk/protective factor	Odd ratio (ODs)	Chi-square (χ^2)	p-value
Malaria	6.2	24.37	0.0000008
Helminthic infection	14.1	58.11	0.0000000001
Measle infection	3.2	7.30	0.007
Diarrheal diseases	4.2	22.10	0.000003
Domestic animals	4.1	22.13	0.000002
River water	1.13	0.03	0.9
vaccination	0.24	21.46	0.000004

227

228 **Discussion**

229 The vast majority of the Noma cases are living in the most deprived and remote regions of
230 sub-Saharan Africa (28). Historically, Noma was most prevalent in the Noma belt region that
231 extends from Senegal to Ethiopia (5). Studies have shown that in countries where the
232 condition is widespread, risk factors such as malnutrition, debilitating diseases like malaria
233 and measles, close residential proximity to livestock are reported (29) (30). Moreover,
234 respiratory or diarrheal syndrome and an altered oral microbiota have been reported as risk
235 factors of Noma (14). The HIV/AIDS pandemic increases the number of cases outside the
236 Noma belt region and is considered to be a viable risk factor of the disease (31). Other risk
237 factors that have been reported in several articles include the absence of breastfeeding,
238 unsafe drinking water, limited access to high-quality health, and food security (1) (32) (33).

239 On the other hand, childhood vaccine coverage has been reported as a protective factor not
240 to develop Noma (34). Diarrheal diseases, drinking river water, living with domestic animals,
241 vaccination coverage, and measles, malaria, and helminthic infections were tested for possible
242 significant association with the development of Noma in this study. The findings of this study
243 supported the above argument. In other words, measles, malaria, helminthic infections,
244 diarrheal diseases, presence of domestic animals at home have been identified as potential
245 risk factors to develop Noma among the cases. On the other hand, vaccination coverage has
246 shown a statistically significant protective effect not to develop Noma among the controls.

247 Malnutrition is considered to be an important risk factor for Noma (35) (36). In Africa, most
248 of the cases were reported during the dry season when food is scarce, and when the incidence
249 of measles is highest (37). The debilitating diseases such as malaria and measles have shown
250 a statistically significant association of being precursors to Noma in this study. Hence the
251 periodicity of onset of the disease in this study could be explained at the dry seasons as food
252 is scarce, and the incidence of measles and malaria often increase (38). Measles and malaria
253 could also be important risk factors because of the associated immunosuppression (39) (40).
254 Furthermore, malnutrition could be regarded as a confounding factor in these associations.
255 However, a further in-depth investigation needs to be carried out.

256 The proportion of vaccination coverage in many developing countries is below the standards
257 recommended by the WHO (41). There is evidence that the occurrence of vaccine-
258 preventable diseases and malnutrition precedes the onset of Noma. The low coverage of
259 vaccination not only increases the risk of morbidity and mortality from vaccine-preventable
260 diseases but is a contributing factor in immunosuppression, which is thought to play a vital
261 role in the sequence of events for Noma development (42). Measle, the only vaccine-

262 preventable disease that has been identified as a risk factor of Noma in this study, could cause
263 immunosuppression among the cases described (43). The diarrheal and helminthic infections
264 that have been identified in this study could also cause immunosuppression. This
265 immunosuppression could be generally confounded by low coverage of vaccination.

266 On the contrary, the protective effect of vaccine coverage that has been identified in this
267 study could be regarded as a positive factor to reduce the burden of the disease. Living with
268 domestic animals is found to be the other risk factor of Noma among the cases studied in this
269 study. This factor could be explained in terms of the lack of proper sanitation. On the other
270 hand, drinking river water has shown neither protective nor causative effect on the
271 development of Noma in this study.

272 The tropical climate, lack of education, rural condition, poor sanitation, and poverty are the
273 leading causes of the high occurrence of Noma (11). A tropical climate characterizes the Afar,
274 Somali, Gambella, Tigray, part of Amhara and Oromia regions. These regions constituted
275 nearly 73% of the total cases admitted to the three Noma treatment facilities in Ethiopia.
276 Climate could be also considered as a potential risk factor for the development of Noma in
277 Ethiopia. Nevertheless, further investigation needs to be carried out.

278 Furthermore, several studies have shown that in countries where the condition is widespread,
279 risk factors such as malnutrition, debilitating diseases like malaria and measles, close
280 residential proximity to livestock are reported (44) (45). Moreover, respiratory or diarrheal
281 syndrome and an altered oral microbiota have been reported as potential risk factors of
282 Noma. The HIV/AIDS pandemic increases the number of cases outside the Noma belt region
283 and is considered to be a viable risk factor of the disease (46) (47). On the other hand,
284 childhood vaccine coverage has been reported as a protective factor for developing the

285 condition. Similarly, in this study measles, malaria, and helminthic infections, diarrheal
286 diseases, and the presence of domestic animals at home have been identified as potential risk
287 factors to develop Noma among the cases. On the other hand, vaccination coverage has
288 shown a statistically significant protective effect not to develop Noma among the controls.

289 In general, the risk factors of Noma reported in the contemporary literature are highly related
290 to poverty (48). In other words, Noma can be considered as an excellent biological parameter
291 of extreme poverty. Hence, policymakers need to be aware that activities against extreme
292 poverty can inevitably avert the occurrence as well as an ill sequela of the disease in
293 developing countries (27).

294 Noma is a disfiguring necrotizing disease of the Oro-facial tissue. It is an “infectious” disease
295 of unknown etiology (49). The burden of the disease can be explained through its high
296 mortality rate and psychosocial morbidity (50). Following the devastating facial
297 disfigurements, survivors are often discriminated against from social life (51). Noma survivors
298 are often left with devastating orofacial defects, which resembles a dramatic amalgamation
299 of oncologic, congenital, and traumatic deformities (52). For instance, a retrospective study
300 that included 22 Noma cases who undergo surgical intervention in Nigeria has revealed 83.3%
301 had lip involvement (53).

302 **Conclusions**

303 In conclusion, this study suggests that disadvantaged children under the age of 10 are
304 predominantly affected by the disease. Most of the victims have shown remarkable Noma-
305 induced facial disfigurements, which exposed them to social discrimination and tangible
306 psycho-social crisis. Living with domestic animals, inaccessibility of adequate vaccination

307 coverage, high morbidity of infectious diseases such as measles, malaria, helminths, and
308 diarrheal diseases have been identified as potential risk/predisposing factors for Noma in
309 Ethiopia. Debilitating conditions, along with malnutrition, can explain the overall risk factors
310 identified in this study. Though adequate data on risk factors are still lacking, the information
311 obtained from this study underscores that Noma must not be neglected.

312 Noma is a debilitating disease primarily affecting the poor and has been called the “face of
313 poverty.” It occurs among the underprivileged society where patients do not have access to
314 proper medical care. Poverty, along with low access to health care, can explain the overall
315 risk factors identified in this study. In other words, Noma can be considered as an excellent
316 indicator of extreme poverty. Improving the economic status of the disadvantaged
317 communities can be considered as the crucial strategy to eradicate Noma globally. History
318 has revealed that Noma can be completely eradicated by enhancing economic progress and
319 reducing poverty. Therefore, strong socio-economic and health policies need to be developed
320 to enable the poorest to afford to acceptable life and access medical care (preventive and
321 surgical rehabilitation), respectively.

322 **Acknowledgment**

323 I would like to acknowledge with gratitude the School of Global Health and Bioethics at
324 EUCLID (Pôle Universitaire EUCLIDE) for supporting the project with useful scientific advice.

325 **References**

- 326 1. Ashok N, Tarakji B, Darwish S, Rodrigues JC, Altamimi MA. A review on noma: a recent
327 update. *Glob J Health Sci.* 2016;8(4):53.

- 328 2. Paster BJ, Falkler Jr WA, Enwonwu CO, Idigbe EO, Savage KO, Levanos VA, et al.
329 Prevalent bacterial species and novel phylotypes in advanced noma lesions. *J Clin*
330 *Microbiol.* 2002 Jun;40(6):2187–91.
- 331 3. Enwonwu CO. Noma: a neglected scourge of children in sub-Saharan Africa. *Bull World*
332 *Health Organ.* 1995;73(4):541.
- 333 4. Giddon DB, Jerome Zackin S, Goldhaber P. Acute necrotizing ulcerative gingivitis in
334 college students. *J Am Dent Assoc.* 1964 Mar 1;68(3):381–6.
- 335 5. Marck KW. A history of noma, the " Face of Poverty". *Plast Reconstr Surg.*
336 2003;111(5):1702–7.
- 337 6. Microbiological understandings and mysteries of noma (cancrum oris) - Falkler - 1999 -
338 *Oral Diseases* - Wiley Online Library [Internet]. [cited 2022 Mar 21]. Available from:
339 <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1601-0825.1999.tb00081.x>
- 340 7. Enwonwu CO, Falkler WA, Idigbe EO, Afolabi BM, Ibrahim M, Onwujekwe D, et al.
341 Pathogenesis of cancrum oris (noma): confounding interactions of malnutrition with
342 infection. *Am J Trop Med Hyg.* 1999;60(2):223–32.
- 343 8. Enwonwu CO. Epidemiological and biochemical studies of necrotizing ulcerative
344 gingivitis and noma (cancrum oris) in Nigerian children. *Arch Oral Biol.*
345 1972;17(9):1357–71.
- 346 9. Bolivar I, Whiteson K, Stadelmann B, Baratti-Mayer D, Gizard Y, Mombelli A, et al.
347 Bacterial diversity in oral samples of children in Niger with acute noma, acute
348 necrotizing gingivitis, and healthy controls. *PLoS Negl Trop Dis.* 2012;6(3):e1556.
- 349 10. Farley E, Mehta U, Srour ML, Lenglet A. Noma (cancrum oris): A scoping literature
350 review of a neglected disease (1843 to 2021). Vinetz JM, editor. *PLoS Negl Trop Dis.*
351 2021 Dec 14;15(12):e0009844.
- 352 11. Farley E, Lenglet A, Ariti C, Jiya NM, Adetunji AS, van der Kam S, et al. Risk factors for
353 diagnosed noma in northwest Nigeria: A case-control study, 2017. *PLoS Negl Trop Dis.*
354 2018;12(8):e0006631.
- 355 12. Tonna JE, Lewin MR, Mensh B. A case and review of noma. *PLoS Negl Trop Dis.*
356 2010;4(12):e869.
- 357 13. Baratti-Mayer D, Gayet-Ageron A, Hugonnet S, François P, Pittet-Cuenod B, Huyghe A,
358 et al. Risk factors for noma disease: a 6-year, prospective, matched case-control study
359 in Niger. *Lancet Glob Health.* 2013;1(2):e87–96.
- 360 14. Braimah RO, Adeniyi AS, Taiwo AO, Ibikunle AA, Gbotolorun OM, Aregbesola SB, et al.
361 Risk Factors and Mortality Rate of Acute Cancrum Oris (noma) in Sokoto North-West
362 Nigeria: A 13-year Survey. 2017;

- 363 15. Whiteson KL, Lazarevic V, Tangomo-Bento M, Girard M, Maughan H, Pittet D, et al.
364 Noma affected children from Niger have distinct oral microbial communities based on
365 high-throughput sequencing of 16S rRNA gene fragments. *PLoS Negl Trop Dis*. 2014
366 Dec;8(12):e3240.
- 367 16. D'Agostino FJ. A review of noma: Report of a case treated with aureomycin. *Oral Surg*
368 *Oral Med Oral Pathol*. 1951;4(8):1000–6.
- 369 17. Koech KJ. Cancrum oris in an adult with human immunodeficiency virus infection: case
370 report. *East Afr Med J*. 2010;87(1):38–40.
- 371 18. Lembo S, Leonibus CD, Francia MG, Lembo C, Ayala F. Cancrum oris in a boy with Down
372 syndrome. *J Am Acad Dermatol*. 2011 Jun 1;64(6):1200–2.
- 373 19. van Niekerk C, Khammissa RAG, Altini M, Lemmer J, Feller L. Noma and cervicofacial
374 necrotizing fasciitis: clinicopathological differentiation and an illustrative case report of
375 noma. *AIDS Res Hum Retroviruses*. 2014 Mar;30(3):213–6.
- 376 20. Vaidyanathan S, Tullu MS, Lahiri KR, Deshmukh CT. Pseudomonas sepsis with Noma: an
377 association? *Indian J Med Sci*. 2005 Aug;59(8):357–60.
- 378 21. Hartman EHM, Damme PAV, Rayatt S, Kuokkanen HOM. Return of the Waltzing Flap in
379 Noma Reconstructive Surgery: Revisiting the Past in Difficult Circumstances. *J Plast*
380 *Reconstr Aesthet Surg*. 2010 Jan 1;63(1):e80–1.
- 381 22. Temporal relationship between the occurrence of fresh noma and the timing of linear
382 growth retardation in Nigerian children - Enwonwu - 2005 - *Tropical Medicine &*
383 *International Health* - Wiley Online Library [Internet]. [cited 2022 Mar 17]. Available
384 from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-3156.2004.01351.x>
- 385 23. Srour ML, Watt B, Phengdy B, Khansoulivong K, Harris J, Bennett C, et al. Noma in Laos:
386 stigma of severe poverty in rural Asia. *Am J Trop Med Hyg*. 2008;78(4):539–42.
- 387 24. Marck KW. Noma: a neglected enigma. *Lancet Glob Health*. 2013;1(2):e58–9.
- 388 25. Berthold P. Noma: a forgotten disease. *Dent Clin*. 2003;47(3):559–74.
- 389 26. Farley E, Ariti C, Amirtharajah M, Kamu C, Oluyide B, Shoaib M, et al. Noma, a
390 neglected disease: A viewpoint article. *PLoS Negl Trop Dis*. 2021 Jun
391 17;15(6):e0009437.
- 392 27. Maley A, Desai M, Parker S. Noma: A disease of poverty presenting at an urban hospital
393 in the United States. *JAAD Case Rep*. 2015;1(1):18–20.
- 394 28. Ogbureke KU, Ogbureke EI. NOMA: a preventable “scourge” of African children. *Open*
395 *Dent J*. 2010;4:201.
- 396 29. Hotez PJ. Forgotten people, forgotten diseases: the neglected tropical diseases and
397 their impact on global health and development. John Wiley & Sons; 2021.

- 398 30. Speiser S, Langridge B, Birkl MM, Kubierna H, Rodgers W. Update on Noma: systematic
399 review on classification, outcomes and follow-up of patients undergoing reconstructive
400 surgery after Noma disease. *BMJ Open*. 2021;11(8):e046303.
- 401 31. Brady-West DC, Richards L, Thame J, Moosdeen F, Nicholson A. Cancrum oris (noma) in
402 a patient with acute lymphoblastic leukaemia. A complication of chemotherapy
403 induced neutropenia. *West Indian Med J*. 1998;47(1):33–4.
- 404 32. Srour ML, Baratti-Mayer D. Why is noma a neglected-neglected tropical disease? *PLoS*
405 *Negl Trop Dis*. 2020 Aug 20;14(8):e0008435.
- 406 33. Dominic C, Farley E, Elkheir N. More than 100 years of neglect: a bibliometric analysis
407 of global research on noma (cancrum oris). *Trans R Soc Trop Med Hyg*. 2021;
- 408 34. Ahlgren M, Funk T, Marimo C, Ndiaye C, Alfvén T. Management of noma: practice
409 competence and knowledge among healthcare workers in a rural district of Zambia.
410 *Glob Health Action*. 2017;10(1):1340253.
- 411 35. Srour ML, Marck K, Baratti-Mayer D. Noma: Overview of a Neglected Disease and
412 Human Rights Violation. *Am J Trop Med Hyg*. 2017 Feb 8;96(2):268–74.
- 413 36. Weledji EP, Njong S. Cancrum Oris (Noma): The Role of Nutrition in Management. *J Am*
414 *Coll Clin Wound Spec*. 2016 Aug 12;7(1–3):50–2.
- 415 37. Sophie H, Thomas F, Jürg U. Noma: epidemiology and global burden of a neglected
416 disease. *ISEE Conf Abstr [Internet]*. 2013 Sep 19 [cited 2022 Mar 21]; Available from:
417 <https://ehp.niehs.nih.gov/doi/abs/10.1289/isee.2013.P-1-14-13>
- 418 38. Yuca K, Yuca SA, Cankaya H, Caksen H, Calka O, Kiriş M. Report of an infant with noma
419 (cancrum oris). *J Dermatol*. 2004 Jun;31(6):488–91.
- 420 39. Pedro K, Smit DA, Morkel JA. Cancrum Oris (noma) in an HIV-positive adult: A case
421 report and literature review. *South Afr Dent J*. 2016 Jul;71(6):248–52.
- 422 40. Costini B, Larroque G, Duboscq JC, Montandon D. [Noma or cancrum oris:
423 etiopathogenic and nosologic aspects]. *Med Trop (Mars)*. 1995 Jan 1;55(3):263–73.
- 424 41. Immunization coverage [Internet]. [cited 2022 Mar 24]. Available from:
425 <https://www.who.int/news-room/fact-sheets/detail/immunization-coverage>
- 426 42. Tall F, Ki-Zerbo G, Ouedraogo I, Guigma Y. [Noma in children in a hospital environment
427 in Bobo-Dioulasso: epidemiologic, clinical and management aspects]. *Odonto-Stomatol*
428 *Trop Trop Dent J*. 2001 Dec;24(96):21–5.
- 429 43. Lazarus D, Hudson DA. Cancrum oris - a 35-year retrospective study. *S Afr Med J*
430 [Internet]. 1997 [cited 2022 Mar 24];87(10). Available from:
431 <https://www.ajol.info/index.php/samj/article/view/157394>

- 432 44. Rowe D, McKerrow N, Uys A, Winstanley T. Case Study: Cancrum oris (noma) in a
433 malnourished HIV-positive child from rural Kwazulu-Natal. *South Afr J HIV Med.*
434 2004;5(3):45–6.
- 435 45. Kaimudin A, Hidajah AC. EPIDEMIOLOGICAL INVESTIGATION OF NOMA IN PAPUA
436 PROVINCE IN 2017. *J Berk Epidemiol.* 2020 Jan 28;8(1):16–25.
- 437 46. Ki-Zerbo GA, Guigma Y. [Noma and HIV infection: apropos of a case at the National
438 Hospital Center in Bobo-Dioulasso (Burkina Faso). *Odonto-Stomatol Trop Trop Dent J.*
439 2001 Dec 1;24(96):26–9.
- 440 47. Prado-Calleros HM, Castillo-Ventura BB, Jiménez-Escobar I, Ramírez-Hinojosa JP, López-
441 Gómez A, García-de-la-Cruz M, et al. Noma and Noma-like disease in HIV/AIDS
442 patients, a comorbid interaction: A systematic review: *J Infect Dev Ctries.* 2018 Feb
443 28;12(02):89–96.
- 444 48. Jain A, Ranka R. The real face of “face of poverty”: an insight on noma. *Hosp Palliat*
445 *Med Int J.* 2017;1(2):49–52.
- 446 49. Baratti-Mayer D, Pittet B, Montandon D, Bolivar I, Bornand J-E, Hugonnet S, et al.
447 Noma: an “infectious” disease of unknown aetiology. *Lancet Infect Dis.* 2003;3(7):419–
448 31.
- 449 50. Srour ML, Marck K, Baratti-Mayer D. Noma: overview of a neglected disease and
450 human rights violation. *Am J Trop Med Hyg.* 2017;96(2):268.
- 451 51. Rickart AJ, Rodgers W, Mizen K, Merrick G, Wilson P, Nishikawa H, et al. Facing Africa:
452 describing noma in Ethiopia. *Am J Trop Med Hyg.* 2020;103(2):613.
- 453 52. Issa AH, Ousmane KAK, Issa EOH, Shen J, Douma MD, Ibrahim AS, et al. Influencing
454 Factors for Social Acceptance of Noma (Cancrum Oris) Patients in Niger: A Hospital
455 Based Retrospective Study [Internet]. Rochester, NY: Social Science Research Network;
456 2021 Jul [cited 2022 Mar 24]. Report No.: ID 3878080. Available from:
457 <https://papers.ssrn.com/abstract=3878080>
- 458 53. Adeniyi SA, Awosan KJ. Pattern of Noma (Cancrum Oris) and Its Risk Factors in
459 Northwestern Nigeria: A Hospital-Based Retrospective Study. *Ann Afr Med.*
460 2019;18(1):17–22.

461

462

463 Appendices

464 Appendix S1: Case Report Form

Heron Gezahegn Gebretsadik, EUCLID UNIVERSITY, Epidemiology of Noma/Cancrum Oris in Ethiopia

Subject Initials **Subject ID** **Date:** / /
Month Day Year

Demographics

Subject Medical Record Number*:

First Name*:

Middle Name (or initial):

Last Name*:

Birthdate*: / /
Month Day Year

<p>Gender*: (check one)</p> <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Unknown or Not Reported	<p>Nationality*: (check one)</p> <input type="checkbox"/> Ethiopian <input type="checkbox"/> Non-Ethiopian <input type="checkbox"/> Unknown or Not Reported
---	--

Race*: (check all that apply)

<input type="checkbox"/> Oromo	<input type="checkbox"/> Tigray
<input type="checkbox"/> Amhara	<input type="checkbox"/> Sidama
<input type="checkbox"/> Somali	<input type="checkbox"/> Other

Other Medical Record Number(s):

Medical Record Number	Hospital/Care Provider (e.g. VA Hospital, Meriter Hospital, EPIC)

Contact Information:

Address:		Unit #:
City:	State:	Zip:
Phone Number: <input type="text"/>	Alternate Phone Number: <input type="text"/>	Email address:
<input type="checkbox"/> Home <input type="checkbox"/> Work <input type="checkbox"/> Cell <input type="checkbox"/> Other	<input type="checkbox"/> Home <input type="checkbox"/> Work <input type="checkbox"/> Cell <input type="checkbox"/> Other	
Preferred method of contact:		

Emergency Contact:

Name:		Unit #:
Address:		Zip:
City:	State:	Email address:
Phone Number: <input type="text"/>	Alternate Phone Number: <input type="text"/>	
<input type="checkbox"/> Home <input type="checkbox"/> Work <input type="checkbox"/> Cell <input type="checkbox"/> Other	<input type="checkbox"/> Home <input type="checkbox"/> Work <input type="checkbox"/> Cell <input type="checkbox"/> Other	
Preferred method of contact:		

*indicates required field

Form Completed By: _____ **Date:** _____

465

Heron Gezahegn Gebretsadik, EUCLID UNIVERSITY, Epidemiology of Noma/Cancrum Oris in Ethiopia

Subject Initials Subject ID Date: / /
 Month Day Year

Clinical Information (Noma/Cancrum Oris)

Body Involved	Diagnosed condition?	Diagnosis/Condition/Surgery	Onset Date Or Year	Prognosis/Healing Status, Healed?
[Upper Lip]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Lower Lip]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Both Lips]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Unilateral]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Bilateral]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Gingiva+Mucosa/AN UG]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Lower Face (Lips, Lower Cheeks, Jawline, Mandible)]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Mid Face (TMJ, Nasal, Zygoma, Oral Commissure, Maxilla, Infra Orbital Margin)]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Mid & Lower Face]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Upper Face (Brow, Upper lid)]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
[Related ADL Limitations]	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No
Other (specify)	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes <input type="checkbox"/> No

ADDITIONAL NOTES: _____

Clinical Data Not Obtained

MEDICAL HISTORY OBTAINED BY: _____

466

467 Appendix S2: Questionnaire

QUESTIONNAIRE

Heron Gezahegn Gebretsadik, EUCLID UNIVERSITY, Epidemiology and Risk Factors of Noma, in Ethiopia.

Date of interview (DD/MM/YYYY): ____/____/____

Interviewer: _____

IDENTIFICATION: STUDY PARTICIPANT

Initials (surname/first name) I__I__I

1) DEMOGRAPHICS OF PARTICIPANT

Sex: Male Female

Date of birth: ____/____/____

Age at development of Noma: _____ years

Area of residence: _____

2) MEDICAL HISTORY

The following questions aim to collect information on past medical history that could potentially related to Noma.

Participant has previously had Noma:

- If yes, specify date:

Yes No

____/____/____

Family history of Noma:

- If yes, specify who and date:

Yes No Unknown

____/____/____

History of other oral health issues:

- If yes, specify condition and date:

Yes No Unknown

___/___/_____

History of diarrheal diseases:

- If yes, specify date and duration:

Yes No Unknown

___/___/_____

History of helminthic infection:

- If yes, specify date and duration:

Yes No Unknown

___/___/_____

History of malaria infection:

- If yes, specify date and duration:

Yes No Unknown

___/___/_____

History of measles infection:

- If yes, specify date and duration:

Yes No Unknown

___/___/_____

Other medical history:

- If yes, specify condition and duration:

Yes No Unknown

Surgical history:

- If yes, specify:

Yes No Unknown

History of childhood vaccination:

- If yes, specify date:

- If yes, indicate:

Yes No Unknown

___ / ___ / _____

Information verified on vaccine card Information provided verbally

3) EXPOSURE

History of living with domestic animals:

- If yes, specify date and duration:

Yes No Unknown

___ / ___ / _____

History of drinking river water:

- If yes, specify date and duration:

Yes No Unknown

___ / ___ / _____